Table 4.

Cancer vaccines in clinical trials based on nucleic acids strategies.

CANCER	Antigen	STRATEGY	NCT NUMBER	PHASE
Acute Myeloid Leukemia	WT-1	RNA-pulsed DC	NCT01686334	Phase 2
	WT-1	RNA-pulsed DC	NCT00834002	Phase 1
Breast	Multiple antigens	DNA vaccine	NCT02157051	Phase 1
	CEA	RNA-pulsed DC	NCT00003432	Phase 1/2
Colorectal	CEA	RNA-pulsed DC	NCT00003433	Phase 1/2
Kidney	hPSMA	DNA	NCT00096629	Phase 1
Lymphoma	Idiotype	DNA	NCT01209871	Phase 1
Melanoma	Multiple	RNA	NCT00204516	Phase 1/2
	tyrosinase-related peptide 2 (TRP2)	RNA-pulsed DC	NCT01456104	Phase 1
	Neo-antigens	RNA	NCT01684241	Phase 1
	Neo-antigens	RNA	NCT02035956	Phase 1
	gp100 and tyrosinase	RNA-pulsed DC	NCT00940004	Phase 1/2
	gp100 and tyrosinase	RNA-pulsed DC	NCT00243529	Phase 1/2
	Multiple	RNA-pulsed DC	NCT01216436	Phase 1
	gp100 and tyrosinase	RNA-pulsed DC	NCT01530698	Phase 1/2
	Multiple	RNA-pulsed DC	NCT00672542	Phase 1
Multiple	CEA	RNA-pulsed DC	NCT00004604	Phase 1
	NY-ESO-1	DNA	NCT00199849	Phase 1
Non Small Cell Lung	Multiple	RNA	NCT00923312	Phase 1/2
	Multiple	RNA	NCT01915524	Phase 1
Prostate	Multiple	RNA	NCT00906243	Phase 1/2
	PSA	DNA	NCT00859729	Phase 1/2
	PSA	RNA-pulsed DC	NCT00004211	Phase 1/2